Medical Products Supplies Companies

B-9 AICT, Gwanggyo-ro 145, Yeongtong-gu, 16229 Suwon-si, Gyeonggi-do
Korea, Republic
Telephone +82 31 8889280
info@oncotag.com

Home

Product Categories

Product categories

03 Diagnostic Tests
03.02 Immunochemistry testing, immunology testing
03.02.03 Diagnostic tests for cancer

Diagnostic tests for cancer

Our products

Product category: Diagnostic tests for cancer
ONCOTAG-M antibody, TAG201
Murine monoclonal antibody used for qualitative identification of normal cells and malignant cells of bile duct sections (paraffin and frozen) and cytocentrifuge preparations.
Oncotag-M Antibody, TAG201 is an antibody to recognize human methionyl-tRNA synthease (MRS) protein that is highly expressed in bile duct carcinomas. Oncotag-M Antibody, TAG201 is useful for distinguishing malignant biliary tumors from normal bile duct cells.

Product category: Diagnostic tests for cancer
ONCOTAG-M Cytology kit, TAG101
Current diagnostic accuracy (eg. PAP stain) of bile duct and pancreatic cancer was 40~60% and 5 years survival rate was less than 10%. Also, 82.4% (pancreas) and 81.3%(bile duct) of cancer patients were suffered by cancer pain.
Diagnostic accuracy for Cholangiocarcinoma of ONCOTAC-M Cytology kit, TAG101 is 97.9% specificity and 96.0% sensitivity.
Furthermore, it can differentiate cancer from atypical cell and benign biliary strictures accurately.

ad: contact information

About Us

Company details
Oncotag Diagonstics contribute to healthy human life by innovating tissue diagnostic solutions and providing high-quality diagnostic product based on intellectual properties.
Without competitive company with our product and superior diagnostic sensitivity comparing with current gold standard staining method, we expect our products will be global standard method in pancreatobilliary cancer cytology test area in near future.
Furthermore new application of oncotag-M biomarker and detection antibody on cancer diagnosis and therapeutic area we are preparing now will add up our commercial value in near future.

ad: company